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Summary
 
Human myeloma are incurable hematologic cancers of immunoglobulin-secreting plasma cells
in bone marrow. Although malignant plasma cells can be almost eradicated from the patient’s
bone marrow by chemotherapy, drug-resistant myeloma precursor cells persist in an apparently
cryptic compartment. Controversy exists as to whether myeloma precursor cells are hemato-
poietic stem cells, pre–B cells, germinal center (GC) B cells, circulating memory cells, or
plasma blasts. This situation reflects what has been a general problem in cancer research for
years: how to compare a tumor with its normal counterpart. Although several studies have
demonstrated somatically mutated immunoglobulin variable region genes in multiple my-
eloma, it is unclear if myeloma cells are derived from GCs or post-GC memory B cells. Immu-
noglobulin (Ig)D-secreting myeloma have two unique immunoglobulin features, including a
 
biased 
 
l
 
 
 
light chain expression and a C
 
m
 
–C
 
d
 
 
 
isotype switch. Using surface markers, we have
previously isolated a population of surface IgM
 
2
 
IgD
 
1
 
CD38
 
1
 
 GC B cells that carry the most
impressive somatic mutation in their IgV genes. Here we show that this population of GC B
cells displays the two molecular features of IgD-secreting myeloma cells: a biased 
 
l
 
 light chain
expression and a C
 
m
 
–C
 
d
 
 
 
isotype switch. The demonstration of these peculiar GC B cells to
differentiate into IgD-secreting plasma cells but not memory B cells both in vivo and in vitro
suggests that IgD-secreting plasma and myeloma cells are derived from GCs.
 
I
 
mmunoglobulin D (IgD) is the major antigen receptor
isotype coexpressed with IgM on the surface of mature
 
naive B cells (1–9). Strikingly, while membrane IgD on
human B cells is preferentially associated to
 
 
 
k
 
 
 
light chain (1,
10), secreted IgD from myeloma cells is preferentially asso-
ciated to 
 
l
 
 light chain (11, 12). The ability of myeloma
cells to secrete IgD appears to be the result of an unusual
C
 
m
 
 
 
to C
 
d
 
 
 
switch mediated by DNA recombination be-
tween sequences within JH–C
 
m
 
 
 
intron and C
 
m
 
–C
 
d
 
 
 
intron
(13–16).
 
 
 
One question has been which B cell differentiation win-
dow corresponds to the stage where IgD myeloma cells
were originated. The answer for this will clarify the long
standing controversial issues (17, 18) of whether the my-
eloma precursors are hematopoietic stem cells (19), pre–B
cells (20), germinal center (GC)
 
1
 
 B cells (21), circulating
memory cells (22, 23), or plasma blasts (24). Although sev-
eral studies have demonstrated somatically mutated Ig vari-
able region genes in multiple myeloma including IgD my-
eloma (23–33), it is unclear if myeloma cells are derived
from GCs or post-GC memory B cells. Here, we report a
population of IgM
 
2
 
IgD
 
1
 
 GC B cells that share three unique
molecular features of IgD myeloma cells: (
 
a
 
) most impres-
sive somatic hypermutation in IgVH genes, (
 
b
 
) C
 
m
 
–C
 
d
 
 iso-
type switch, and (
 
c
 
) 
 
l
 
 light chain expression. These GC B
cells were shown to differentiate into plasma cells but not
memory B cells, suggesting that IgD-secreting myeloma are
derived from B cells at GC stage but not at memory stage. 
 
Materials and Methods
 
Assay for S
 
m
 
–
 
s/d
 
 
 
Recombination. 
 
Genomic DNAs were ex-
tracted from 3 
 
3 
 
10
 
7
 
 EBV transformed cells or 10
 
5
 
 fresh purified
cells, according to the standard procedure. Genomic DNA was
submitted to PCR amplification using the 5
 
9
 
 primer P3 (5
 
9
 
-CG-
GCAATGAGATGGCTTT-3
 
9
 
) and the 3
 
9
 
 primer P4 (5
 
9
 
-
GGCAAACTGTCATGG GTT-3
 
9
 
), as shown in Fig. 1
 
A
 
. All
PCR reactions were performed with Taq polymerase (Perkin-
Elmer Corp., Norwalk, CT) using the reaction buffer provided
by the manufacturers and a DNA thermal cycler (Perkin-Elmer
 
1
 
Abbreviations used in this paper:
 
 CDR, complementarity determining re-
gion; GC, germinal center; s, surface.
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Corp.) with 35 cycles of 1 min denaturation at 94
 
8
 
C, 2 min
primer annealing at 60
 
8
 
C, and 3 min extension at 72
 
8
 
C. Com-
plete extension of the products was then performed by a final 10-
min incubation at 72
 
8
 
C. For DNA sequencing, PCR products
were cloned using the TA cloning kit (Invitrogen, Carlsbad, CA).
Individual bacterial colonies were randomly picked and extracted
plasmids were sequenced in an automated DNA sequencer (Ap-
plied Biosystems, Foster City, CA) on both strands.
 
Measurements of Ig Secretion. 
 
IgG, IgA, and IgM measurements
were performed using ELISA as previously described (34). For
IgD measurement, flat-bottomed 96-well plates were coated with
2 
 
m
 
g/ml of monoclonal anti-IgD antibodies (Nordic Immuno-
logical, Tiburg, The Netherlands) overnight at 4
 
8
 
C. After six
washes, plates were first saturated for 3 h at 37
 
8
 
C with RPMI
(GIBCO BRL, Gaithersburg, MD) containing 10% fetal calf se-
rum (GIBCO BRL), and then incubated overnight at 4
 
8
 
C with
appropriate dilutions of the assays and the standard purified my-
eloma IgD (The Binding Site, Birmingham, UK). Plates were
washed six times and incubated with goat anti-IgD-biotin (Sigma
Chemical Co., St. Louis, MO) at 2 
 
m
 
g/ml for 2 h at room tem-
perature. After six washes, streptavidin–alkaline phosphatase (Sigma
Chemical Co.) diluted 1/10,000 was added for 1 h at room tem-
perature and enzymatic activity was revealed by 
 
p
 
-nitrophenyl
phosphate (Sigma Chemical Co.) and read at 490 nm on a V
 
max
 
spectrophotometer. The absence of cross-reactivities with human
IgG, IgA, IgM, IgE, Ig
 
k
 
, and Ig
 
l
 
 was checked, and values were
reported to a standard curve using a purified myeloma IgD. 
 
Analysis of Ig Light Chain Expression. 
 
5 
 
3 
 
10
 
3
 
 B cells were
transformed by EBV during a 2-wk culture in a CD40 system
with 10 
 
m
 
l of EBV containing B95-8 supernatant in a round-bot-
tomed 96-well plate. Cloning was performed by culturing 1 cell/
 
well. The clones derived from surface (s)IgM
 
2
 
IgD
 
1
 
CD38
 
1
 
 GC
B cells were selected by their sIgM
 
2
 
IgD
 
1
 
 phenotype and clones
derived from sIgM
 
1
 
IgD
 
1
 
CD38
 
1
 
 B cells were selected according
to their sIgM
 
1
 
 phenotype. VH gene expression by EBV clones
was analyzed by VH–C
 
d
 
 PCR amplification and sequence analy-
ses using primers specific for each VH family and C
 
d
 
 region.
Among the 76 EBV clones, the V gene usage of 12 EBV clones
derived from sIgM
 
2
 
IgD
 
1
 
CD38
 
1
 
 GC B cells were determined.
One VH1, two VH5, fourVH3, and five VH4 were identified.
Furthermore, light chain expression by EBV clones was analyzed
by flow cytometry with anti-Ig
 
k
 
-FITC and anti-Ig
 
l
 
-FITC (Kal-
lestad, Austin, TX).
 
Isolation of Tonsillar Plasma Cells. 
 
In brief, tonsillar cells were
centrifuged through 1.5% BSA at 10 
 
g
 
 for 10 min. CD20
 
2
 
CD38
 
11
 
 plasma cells were then isolated by cell sorting. To isolate
IgD
 
1
 
 and IgD
 
2
 
 plasma cells, after centrifugation through 1.5%
BSA, cells were first stained with anti-CD38-PE (Becton Dickin-
Figure 1. Cm–Cd switch recombinations in IgM2IgD1CD381 GC B cells. (A) Schematic representation of the Sm–s/d and s/m–S/m recombinations
(14–16). (B) PCR amplification of Sm–s/d recombination. Lane A, IgM1IgD1CD381 GC founder cells; lane B, IgM2IgD1CD381 GC B cells; lanes C,
D, and E, EBV clones from IgM2IgD1CD381 cells; lanes F, G, and I, EBV clones from IgM1IgD1CD381 cells. (C) DNA sequences of Sm–s/d junc-
tional regions from IgM2IgD1CD381 cells. Upper strings, germline sequences of the Sm region; lower strings, germline sequences of the s/m–s/d intron.
The central string represents the sequences of cloned PCR products. Homologous nucleotides are linked by vertical bars. Arrowed figures, base numbers,
base No. 1 being the first 39 of the VDJ region. (D) Schematic representation of the break points.
Table 1. Percentage and Number of Clones Expressing Igk and Igl 
Derived from Three CD381 GC B Cell Subsets
Clones derived from
Percentage of clones
expressing Igl Number of clones
sIgM1IgD1CD381 47 83
sIgD2CD381 32 53
sIgM2IgD1CD381 99 711171 Arpin et al.
Figure 2. Differentiation of
IgM2IgD1CD381 B cells into IgD1
plasma cells in vitro. IgD, IgG, IgA,
and IgM secretion (A) and IgD im-
munostaining (B and C) of IgM2
IgD1CD381 B cells cultured for 2
wk in the presence of IL-10, IL-2,
and CD40 ligand transfected murine
fibroblasts. Ig contents were mea-
sured by ELISA and results are given
in mg/ml. Original magnifications of
microphotographs are 100 (B) and
1,000 (C).
Figure 3. Ig heavy chain expression by tonsillar plasma cells. Immunoenzymatic staining of tonsillar tissue sections (A, B, and C) or plasma cell cytospin
preparations (D and E). (A) Double red anti-IgD and blue anti-CD38 staining showing purple IgD1 plasma cell within a GC and red IgD1 follicular
mantle (FM) B cells. Original magnification: 400. (B and C) Double red anti-IgD and blue anti-Ki67 staining showing red IgD21 plasma cells under the
tonsillar epithelium (EP). Original magnifications are 100 (B) and 400 (C). (D) Single red anti-IgD staining showing IgD1 plasma cells among purified
tonsillar plasma cells. Original magnification: 1,000. (E): Double blue anti-IgD and red anti-IgM staining showing exclusive expression by plasma cells of
each isotype. Original magnification: 1,000.1172 Extensively Mutated IgVH Gene, Cm–Cd Switch, and l Light Chain Expression
son, Mountain View, CA). They were permeabilized by an over-
night incubation with 1% paraformaldehyde at 48C. Intracellular
IgD was stained with a mouse anti-IgD antibody-FITC (Dako
Corp., Carpinteria, CA). CD3821 plasma cells were finally sepa-
rated into intracellular IgD1 or IgD2 plasma cells by cell sorting.
Sequence Analysis of the VH5 Transcripts.  This was done ac-
cording to our established methods (35–37). In brief, messenger
RNA was extracted from 2.5 3 104 plasma cells and cDNA was
obtained by reverse transcription. Full-length VH5–d transcripts
were amplified with 59LVH5 primer (59-CCCGAATTCATG-
GGGTCAACCGCCATCCT-39) with 39 primer HCd (59-GGC-
GGCCGCTGGCCAGCGGAAGATCTCCTTCTT-39), HCm
(59-TGGGGCGGATGCACTCCC-39), or HCg (59-CAGGGG-
AAGACCGATGG-39) with Taq polymerase (Perkin-Elmer Corp.).
PCR reaction was 35 cycles of 1 min denaturation at 948C, 2 min
of primer annealing at 608C, and 30 min at 728C. The frequency
of Taq error in our lab is ,2%. The PCR products were cloned,
using the TA cloning kit (Invitrogen). Plasmids extracted from
individual bacterial colonies were sequenced. 
Results
Hypermutated sIgM2IgD1CD381 GC B Cells Have Un-
dergone Cm–Cd Switch by Recombination between Sm and the
Pentamer-rich s/d Region. We have previously identified a
population of sIgM2IgD1CD381 GC B cells that contain
extensively mutated Ig variable region genes (36). An in-
triguing link between these B cells and IgD-secreting my-
eloma cells is the rare single surface expression of IgD iso-
type of Igs. Such a phenotype can only be explained by
either Cm gene deletion as observed in IgD myeloma cells
(14, 15) and in unfractionated cells from normal tonsils (16)
of alternative splicing of m–d messenger RNAs, as observed
in sIgM1IgD2 B cells. To clarify this issue, PCR primers
were designed for probing recombination events between
the 442-bp s/m region and the 443-bp S/m region or be-
tween Sm and the pentamer-rich region s/d (Fig. 1 A). In
three tonsillar samples, Sm–s/d recombination but not
sm–Sm recombination was detected in sIgM2IgD1CD381
GC cells and their derived EBV transformed clones, but
not in sIgM1IgD1CD381 GC founder cells (37) and their
EBV-derived clones (Fig. 1 B presents the result from one
tonsil sample). To determine the Sm–s/d break points, PCR-
generated DNA products were cloned and sequenced. Fig.
1 C shows the sequences of four Sm–s/d junctions ob-
tained from freshly isolated sIgM2IgD1CD381 GC B cells
and their EBV clones. The four break points, which are
presented in a schematic diagram in Fig. 1 D, demonstrate
that the Cm–Cd switch had occurred in sIgM2IgD1CD381
GC B cells. 
Hypermutated sIgM2IgD1CD381 GC B Cells Express l
Light Chains. Since the second feature of IgD secreting
myeloma was its preferential Igl light chain expression (11,
12), we analyzed the light chain expression of a panel of
EBV transformed clones derived from discrete B cell sub-
sets of two tonsil samples (Table 1). Although 39 out of 83
EBV clones from sIgM1IgD1CD381 GC founder cells and
17 out of 53 EBV clones from sIgD2CD381 GC B cells
express l light chains, 75 out of 76 EBV clones from
sIgM2IgD1CD381 GC cells express l light chains. VH se-
quence analysis showed that most clones were clonally in-
dependent (see Materials and Methods). These data dem-
onstrate that sIgM2IgD1CD381 GC B cells display the
second feature of IgD myeloma cells: preferential expres-
sion of l light chain. 
Table 2.  Total Tonsillar PCs Secrete IgD
Experiment No. 1 Experiment No. 2
PCs GCs PCs GCs
IgM ,40 ,40 ,40 ,40
IgD 11 6 1 ,1 29 6 1 ,1
IgG 501 6 64 25 6 5 209 6 15 43 6 1
IgA 205 6 18 88 6 1 116 6 19 12 6 1
IgE ,0.4 ,0.4 ,0.4 ,0.4
CD202CD3821 PCs and CD201CD381 GCs were isolated by FACSÒ
sorting. 2 3 104 cells were cultured overnight in 200 ml Iscove medium.
Ig contents were measured by ELISA assay. Data are given in ng/ml (mean
6 SD).
Table 3. IgD Sequences from PC Show a High Rate of Somatic 
Mutations as Well as a Strong Clonal Relationship
VDJ asso-
ciated with
Mutations (number
per VDJ segment)
Clonality (percent
of related sequences)
Cm 4 6 2 (1–9, n 5 19) 21 (4/19)
Cg 10 6 8 (1–31, n 5 62) 5 (3/62)
Cd 21 6 12 (1–65, n 5 52) 83 (43/52)
VH5–Cd sequences were amplified from PC cDNA and compared to
the VH5–Cm and VH5–Cg sequences. The number of mutations per
VDJ segments is given as mean 6 SD (range, n). The degree of clonality
is represented by the percentage of related sequences analyzed. Cm, Cg,
and Cd derive from 1, 2, and 3 different tonsil samples, respectively.
Figure 4. Analysis of Ig heavy chain variable region genes of IgD1 plasma cells. (A) Schematic representation of VH5–Cd sequences from plasma cells
of one representative tonsil. Leader, CDR1, CDR2, and D/J regions are boxed. Sequence names are listed on the left (Seq.) and boxed names represent
clonally related sequences. Total mutation numbers are listed on the right. Germline sequences of D regions were not assigned. Mutations are represented
as replacement (circle with stem) and silent (stem). (B) Nucleotide sequences from the largest clone. The upper string gives the nucleotides of the VH5–1
germline sequence, the D region from the less mutated sequence (192), and the JH6 germline sequence. CDR1, CDR2, and CDR3 are boxed. Dashes,
matches to the first string. Mutated bases are indicated. (C) Genealogical tree from this clone. Each analyzed sequence is indicated by its circled name,
whereas common predicted intermediates are boxed. The number of mutations between sequences are indicated on the line joining them, and total se-
quence mutations are within brackets.1173 Arpin et al.1174 Extensively Mutated IgVH Gene, Cm–Cd Switch, and l Light Chain Expression
Hypermutated sIgM2IgD1CD381 GC B Cells Display Poor
Ability to Undergo Further Isotype Switch In Vitro. As sIgM2
IgD1CD381 GC B cells had lost a major part of the Sm re-
gion after Cm–Cd switch (Fig. 1 D), it was anticipated that
they would not undergo further isotype switch. Indeed,
sIgM2IgD1CD381 GC B cells differentiated mainly into
IgD-secreting cells after 10 d of culture on CD40 trans-
fected L cells with IL-2 and IL-10 (Fig. 2), a culture condi-
tion under which human naive B cells undergo isotype
switch to IgG and differentiate into IgG-secreting cells (38,
39). Thus, sIgM2IgD1CD381 GC B cells display two com-
mon features with IgD secreting myeloma cells, i.e., the
Cm–Cd isotype switch and the preferential l light chain
expression, and they could differentiate into normal IgD-
secreting cells in vitro. 
IgD-secreting Plasma Cells Represent a Major Population of
Plasma Cells in Human Tonsils. We have previously dem-
onstrated that hypermutated sIgM2IgD1CD381 GC B
cells could not give rise to circulating memory cells in
blood (36). However, IgD1 plasma cells were previously
identified in human tonsils by immunohistology (40, 41),
suggesting that sIgM2IgD1CD381 GC B cells may differ-
entiate into IgD-secreting plasma cells. An immunohis-
tochemistry analysis performed on four randomly selected
tonsillar samples with anti-IgD showed that IgD1 plasma
cells represent an average of 16% (range 6–20%) of total
CD3821 plasma cells. They were found either within GCs
(Fig. 3 A) or within mucosal epithelium (Fig. 3, B and C),
as reported earlier for IgA1 plasma cells (42). To further
characterize IgD1 plasma cells, tonsillar plasma cells were
isolated by cell sorting according to their CD3821CD202
phenotype as previously described. In agreement with the
immunohistological analyses on tissue sections, plasma cells
isolated from five tonsil samples contains 17% (3–48%)
IgD1 and only 2–5% IgM1 cells (Fig. 3 D). Double anti-
IgD and anti-IgM staining showed that plasma cells contain
either IgM or IgD, but never both isotypes (Fig. 3 E). Fur-
thermore, IgG, IgA, and IgD were the major Ig isotypes
secreted by these plasma cells during overnight cultures
(Table 2). The question is do IgD-secreting plasma cells in
tonsils indeed represent the progeny of IgM2IgD1 GC B
cells and the normal counterpart of IgD-secreting myeloma
cells? 
IgD-secreting Plasma Cells Have Undergone Extensive Somatic
Mutation and Display Striking Clonal Relatedness. The first im-
portant feature of sIgM2IgD1CD381 GC B cells is their
extensively mutated IgV genes. Thus, VH5–d, VH5–m, and
VH5-g transcripts were amplified from 10,000 plasma cells
of each of the three tonsil samples. The PCR products
were then sequenced. Consistent with the surface or cyto-
plasmic Ig expression of different cell subsets, VH5–d tran-
scripts could only be amplified from IgD1CD382 naive B
cells and CD3821CD202 plasma cells, but not from IgD2
CD381 GC B cells and IgD2CD382 memory B cells (data
not shown). The 19 VH5–m sequences had an average of
four mutations per sequence and four sequences displayed
clonal relatedness (Table 3). The 62 VH5–g sequences had
an average of 10 mutations/sequence and three sequences
displayed clonal relatedness. These mutation frequencies
are similar to that of the VH5–m and VH5–g transcripts of
GC B cells and memory B cells previously described (35,
43), indicating the GC origin of these plasma cells. The 52
VH5–d transcripts had accumulated an average of 21 muta-
tions/sequence. 43 out of 52 sequences displayed clonal re-
latedness. (Clonal relatedness means that more than two se-
quences within the same tonsil sample are derived from
one cell by somatic mutation.) The VH5–d sequences of
plasma cells from one representative tonsil (Fig. 4 A) dis-
play three features previously observed in the VH5–d se-
quences of sIgM2IgD1CD381 GC B cells (36): (a) their
mutation frequency being two- to threefold higher than
that of m and g transcripts, (b) replacement mutations not
being concentrated within complementarity determining
regions (CDRs), and (c) a high frequency of clonal related-
ness. The genealogical trees deduced from the clonally re-
Figure 5. Cm–Cd switch recombinations in IgD1 plasma cells of three
tonsil samples. (A): PCR amplification of Sm–s/d recombinations of ge-
nomic DNA from IgD1 (lanes D1) and IgD2 (lanes D2) plasma cells. (B)
DNA sequences of Sm–s/d junctional regions from IgD1 plasma cells.
Upper strings, germline sequences of the Sm region; lower strings, germline
sequences of the s/m–s/d intron. The central string represents the se-
quences of cloned PCR products. Homologous nucleotides are linked by
vertical bars. Arrowed figures, the base numbers, base No. 1 being the first
39 of the VDJ region. (C) Schematic representation of the break points.1175 Arpin et al.
lated sequences (Fig. 4, B and C) indicate that somatic mu-
tations have been accumulated during the extensive clonal
expansion of IgD plasma cell precursors, the sIgM2IgD1
CD381 GC B cells. Since an average of 16% of tonsillar
plasma cells secrete IgD and only z2–5% of human B cells
use VH5 genes, each tonsil sample may contain only 30–80
IgD-VH5–expressing plasma cells. These cells may repre-
sent the descendents of a single GC and may explain the
observed restricted V gene usage.
IgD-secreting Plasma Cells Have Undergone Cm–Cd Switch.
To determine whether IgD-secreting plasma cells have un-
dergone Cm–Cd switch, CD3821 total tonsillar plasma cells
were separated into intracellular IgD1 and intracellular
IgD2 subsets by a two-color immunofluorescence cell sorter.
Sm–s/d junctions were amplified from DNA of 10,000 cells
of each subset. Fig. 5 A shows that Sm-sd junction can be
amplified from IgD1 plasma cells of three tonsil samples,
but not from IgD2 plasma cells. Fig. 5 B shows the se-
quences of three examples of Sm–s/d junctions from IgD1
plasma cells. The corresponding break points are depicted
in Fig. 5 C.
IgD-secreting Plasma Cells Preferentially Express l Light
Chains. To determine the light chain expression of nor-
mal IgD-secreting plasma cells, double staining with anti-
IgD (blue) and anti-Igk (red) as well as anti-IgD (blue) and
anti-Igl (red) were performed on serial sections of three
tonsil samples. Although few IgD1 plasma cells expressed
Igk light chain (most cells are single stained blue; Fig. 6, A
and B), .90% were shown to express Igl light chain (dou-
ble stained purple; Fig. 6, C and D).
IgD-secreting Myeloma Cells Have Undergone Somatic Muta-
tion in Their Ig Variable Region Genes. A previous study by
Kiyoi et al. showed that four cases of IgD-secreting my-
eloma contained somatically mutated IgV genes (32). We
analyzed the VH sequences of two well-characterized hu-
man IgD-secreting myeloma. VH sequence from patient 1
(15) displays 40 nucleotide differences from the three clos-
est germline sequences (VH3-33/DP50, VH3-30.3/DP46,
Figure 6. Ig light chain expression by tonsillar plasma cells. (A and B) Double blue anti-IgD and red anti-Igk staining showing many single stained blue
Igk2IgD1 plasma cells and a few double stained purple Igk1IgD1 plasma cells. (C and D) Double blue anti-IgD and red anti-Igl staining on a serial sec-
tion, showing many double stained Igl1IgD1 plasma cells in purple and a few Igl2IgD1 plasma cells single stained in blue. Original magnifications: 100
(A and C) and 400 (B and D).1176 Extensively Mutated IgVH Gene, Cm–Cd Switch, and l Light Chain Expression
and VH3-30.5/DP49; Fig. 7). VH sequence from patient 2
(14) displays 85 nucleotide differences from the closest germ-
line sequence (VH1-69/DP10; Fig 7). Exhaustive analyses
and searches through different Ig databases from two differ-
ent laboratories failed to identify other closest germline se-
quences. These data further suggest the GC origin of IgD-
secreting myeloma cells.
Discussion
IgD was first discovered by Rowe and Fahey as a unique
myeloma protein (33). IgD-secreting myeloma cells were
found to display two unusual features that could not fit into
the current model of antigen-driven B cell development
(44). First, while the membrane IgD on B cells shows a
predominance of the Igk type, more than two thirds of all
known IgD myeloma proteins were shown to belong to
the lambda type (11, 12). Second, IgD-secreting myeloma
cells had undergone a unusual Cm–Cd switch. This raises
the question of whether the features of IgD-secreting my-
eloma cells represent only a malignant event or reflect a
normal B cell maturation pathway.
Here we demonstrate that hypermutated sIgM2IgD1
CD381 GC B cells, which represent 2–5% of normal ton-
sillar B cells (36), may represent the precursors of normal
and malignant IgD-secreting plasma cells. First, significant
numbers of normal IgD-secreting plasma cells were identi-
fied in human tonsils (40, 41). In particular, both sIgM2
IgD1CD381 B cells and IgD1 plasma cells could be found
within the same GCs. Second, CD40-activated sIgM2
IgD1CD381 GC B cells were shown to directly differenti-
ate into IgD-secreting cells when cultured with IL-2 and
IL-10. Third, both sIgM2IgD1CD381 GC B cells and
normal IgD-secreting plasma cells displayed a similar somatic
hypermutation rate. Fourth, both sIgM2IgD1 CD381 GC
B cells and normal IgD-secreting plasma cells had been
originated from a few cells that had undergone impressive
clonal expansion and somatic mutation within GCs. Fifth,
like IgD-secreting myeloma cells, both cell types preferen-
tially expressed the Igl light chain and had undergone
Cm–Cd switch. 
Previous studies have shown that IgVH and IgVL genes
of IgG, IgA, and IgD myeloma contain extensive somatic
mutation (23–33). These findings strongly suggest that
IgD-secreting myeloma cells are not derived from the trans-
formation of stem cells (19) or pre–B cells (20), but from GC
B cells or post-GC memory B cells. Our previous study
demonstrated sIgM2IgD1CD381 GC B cells did not ma-
ture into blood memory B cells. This, together with the
present finding that sIgM2IgD1CD381 GC B cells differ-
entiate into IgD-secreting plasma cells, suggests that IgD-
secreting myeloma cells are derived from B cells at the GC
B cell stage, but not at the post-GC memory B stage.
The identification of sIgM2IgD1CD381 GC B cells and
IgD1 plasma cells defines a novel GC B cell development
pathway in human, characterized by (a) a nonclassical iso-
type switch from Cm to Cd, (b) a light chain shift from k to
l, (c) the impressive oligoclonal expansion and somatic hy-
permutation, and (d) generation of IgD-secreting plasma
cells. The molecular triggers and functional implications of
the Cm–Cd switch, the k–l light chain shift, and the enor-
mous clonal expansion and somatic mutation in sIgM2IgD1
CD381 GC B cells are currently unknown. The k-l light
chain shift may result from a secondary light chain rear-
rangement (receptor editing; references 45, 46) in GCs, as
recently demonstrated in mouse GC B cells (47–50).
The identification of a significant number of IgD1
plasma cells in human tonsils also challenges the previous
hypothesis that IgD functions simply as an antigen receptor,
but not as a secreted antibody. This, together with recent
identification of IgD1 memory B cells in human bone mar-
row (51) and virus-specific IgD-secreting plasma cells in
the spleen of mice (52), strongly suggests that IgD plays an
important role in certain types of humoral immune re-
sponses. 
Figure 7. Analysis of Ig heavy chain variable region genes of IgD my-
eloma cells. Schematic representation of VH sequences from IgD my-
eloma cells of two samples. Patient 1 (15) shows 40 nucleotide substitu-
tions, and patient 2 (14) shows 85 nucleotide differences plus one 9-bp
deletion (between brackets). Mutations are represented as replacement (circle
with stem) and silent (stem). 
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